Olga Riabova

Olga Riabova

Auto-generated profile, based on publicly available information

Olga Riabova

Federal Research Center of Biotechnology of the RAS, Moscow, Russia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Antiviral Research
Verified
Journal Article
Closed access
HBHeike Braun
Heike Braun
Johannes KirchmairJohannes Kirchmair
Johannes Kirchmair
MWMark J. Williamson
Mark J. Williamson
VMVadim Makarov
Vadim Makarov
OROlga B. Riabova
Olga B. Riabova
MSMichaela Schmidtke
Michaela Schmidtke

28 September 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
BGBrindha Gap-Gaupool
Brindha Gap-Gaupool
SGSarah M. Glenn
Sarah M. Glenn
EMEmily Milburn
Emily Milburn
OTObolbek Turapov
Obolbek Turapov
MCMarialuisa Crosatti
Marialuisa Crosatti
GMGalina Mukamolova
Galina Mukamolova
During infection Mycobacterium tuberculosis (Mtb) forms physiologically distinct subpopulations that are recalcitrant to treatment and undetectable using standard diagnostics. These difficult to culture or differentially culturable (DC) Mtb are revealed in liquid media, their revival is often stimulated by resuscitation-promoting factors (Rpf) and prevented by Rpf inhibitors. Here, we investigated the role of nitric oxide (NO) in promoting the DC phenotype. Rpf-dependent DC Mtb were detected following infection of interferon-γ-induced macrophages capable of producing NO, but not when inducible NO synthase was inactivated. After exposure of Mtb to a new donor for sustained NO release (named NOD), the majority of viable cells were Rpf-dependent and undetectable on solid media. Gene expression analyses revealed a broad transcriptional response to NOD, including down-regulation of all five rpf genes. The DC phenotype was partially reverted by over-expression of Rpfs which promoted peptidoglycan remodelling. Thus, NO plays a central role in the generation of Rpf-dependent Mtb, with implications for improving tuberculosis diagnostics and treatments.

27 April 2022 in Antiviral Research
Verified
Journal Article
Closed access
LALyudmila Alimbarova
Lyudmila Alimbarova
AEAnna Egorova
Anna Egorova
OROlga Riabova
Olga Riabova
NMNatalia Monakhova
Natalia Monakhova
VMVadim Makarov
Vadim Makarov

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
AKAngela Koryakova
Angela Koryakova
VSViktoriya Scherbakova
Viktoriya Scherbakova
OROlga Riabova
Olga Riabova
YKYurii Kazaishvili
Yurii Kazaishvili
RBRoman Bolgarin
Roman Bolgarin
VMVadim Makarov
Vadim Makarov
Macozinone (MCZ) is the newest first-in-class clinical-stage benzothiazinone-based drug candidate for the treatment of tuberculosis. Yet, the extremely low oral bioavailability of MCZ, a major problem in clinical trials, needed to be addressed, and we are pleased to present our attempts to solve this issue.

9 August 2022 in ChemMedChem
Verified
Journal Article
Closed access
OROlga Riabova
Olga Riabova
AEAnna Egorova
Anna Egorova
ALAlexander Lepioshkin
Alexander Lepioshkin
YLYan Li
Yan Li
KVKerstin Voigt
Kerstin Voigt
VMVadim Makarov
Vadim Makarov

1 June 2007 in Antiviral Research
Verified
Journal Article
Closed access
VKV Kuzmin
V Kuzmin
EMEugene Muratov
Eugene Muratov
AAA. Artemenko
A. Artemenko
IVI. Volineckaya
I. Volineckaya
VMVadim Makarov
Vadim Makarov
MSMichaela Schmidtke
Michaela Schmidtke